Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Business

Research and Markets: Osteoporosis Therapeutics - a Global Market Perspective: the Most Comprehensive Report in Geographic Coverage and Vertical Market Analyses


Print article Print article
© Business Wire 2009
2009-11-26 15:53:02 -

Research and Markets ( www.researchandmarkets.com/research/2070d2/osteoporosis_thera : ) has announced the addition of the " Osteoporosis Therapeutics - A Global Market Perspective : " report to their offering.

Osteoporosis, the most common type of metabolic bone diseases, is an implacable epidemic growing rapidly in regions of North America, Europe, and Japan. Afflicting millions of people across the world, the potentially life-threatening disease - osteoporosis poses a major clinical challenge to the medical world. Major therapeutic classes currently available include bisphosphonates, Estrogen Replacement Therapy (ERT) drugs, calcitonins and Selective Estrogen Receptor Modulators (SERMs). Parathyroid Hormone (PTH)-based drugs comprise the most recent genre of therapeutics with new bone-forming potential. As osteoporosis is asymptomic, several cases of osteoporosis are detected only after experiencing

a fracture.

These and other market data and trends are presented in "Osteoporosis Therapeutics: A Global Market Perspective" by BizAcumen, Inc. This report is designed to be the most comprehensive in geographic coverage and vertical market analyses.



Key Topics Covered:

METHODOLOGY



- Study Reliability and Reporting Limitations
- Disclaimers
- Quantitative Techniques & Reporting Level


OUTLOOK


INDUSTRY OVERVIEW



- Osteoporosis Therapeutics: An Evolutionary Scan
- "A Sketch of the Present Industry Scenario"
- Facts & Figures: The Osteoporosis Primacy
- Snapshots
- Factors Influencing Demand
- Competitive Landscape
- Market Trends and Issues
- Can New Treatments Beat the Gold Standard?
- Oral Calcitonin Likely to Emerge as Wonder Drug
- New Bisphosphonates Challenge Established Brands
- Side Effects of HRT Fuel Natural Alternatives Sales
- Bone Formation Drugs Augur New Prospects
- Estrogen Replacement Therapy: Will Dosing Make a Difference?
- Is Prevention Always Better Than Cure?
- Peptide-Based Osteoporosis Therapy Gaining Ground
- Polymorphism- A Potent Diagnostic Marker
- Bisphosphonates - The Other Side
- Efficacy of Evista Under the Scanner


MAJOR THERAPEUTIC CLASSES: A GLOBAL PERSPECTIVE



- ERT Drugs
- Ups and Downs in the ERT Market
- Bisphosphonates
- The leading Therapeutic Market
- SERMs (Selective Estrogen Receptor Modulators)
- Market Overview
- Calcitonins
- Market Overview


PRODUCT FACTS



- Bisphosphonates
- Hormone Replacement Therapy/ Estrogen Replacement Therapy
- Estrogens
- Estrogens/Progesterones
- Calcitonins
- Selective Estrogen Receptor Modulators (SERMs)
- Other Therapeutics


MAJOR CLINICAL TRIALS/FINDINGS


CORPORATE DEVELOPMENTS



- Schering-Plough Acquires Organon BioSciences
- Faes Farma Signs Marketing Agreement with Roche and GlaxoSmithKline
- Alethia and Emerillon Collaborate on Osteoporosis Therapies
- Ipsen Enters into Co-marketing Agreement with MSD
- Unigene Enters into Agreement with Novartis
- Pharming Group Granted Subsidies to Develop Osteoporosis Drugs
- Procter & Gamble Terminates Nasal Spray Collaboration with Nastech- Pharmaceutical
- GSK & NPS Collaborate for Phase II Clinical Study of Calcilytics
- Radius Initiates Phase II Trials for BA058
- Novartis and Nordic Initiate Phase III Clinical Trial of Oral Salmon Calcitonin
- Medivir Initiates First Human Trials for MIV-701
- P&G Receives FDA Approval for New Dosage of Actonel
- Takeda Introduces Benet for Osteoporosis Treatment
- Labtec Obtains Approval to Market Hormone Replacement Patch in Europe
- Wyeth Obtains Conditional Approval for Osteoporosis Drug from FDA
- Merck's New Dosage of FOSAMAX PLUS D Gains FDA Approval
- Japanese Pharma Majors Receive Approval for Generic Osteoporosis Drug


MAJOR PLAYERS



- Eli Lilly and Company (US)
- F.Hoffmann-La Roche Ltd (Switzerland)
- Merck & Co., Inc. (US)
- Novartis AG (Switzerland)
- Novo Nordisk A/S (Denmark)
- Organon
- Procter & Gamble Pharmaceuticals Inc. (US)
- Sanofi-Aventis SA (France)
- Servier SA (France)
- Solvay Pharmaceuticals Inc. (US)
- Unigene Laboratories, Inc. (US)
- Wyeth (US)


GLOBAL MARKET ANALYTICS


REGIONAL OVERVIEW


COMPANIES PROFILED


For more information visit www.researchandmarkets.com/research/2070d2/osteoporosis_thera :



Research and MarketsLaura Wood, Senior Manager, press@researchandmarkets.com : mailto:press@researchandmarkets.com U.S.

Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716


Author:
Hossam Abdel-Kader
e-mail
Web: www.pr-inside.com/
Phone: +43 1 9582319

Disclaimer: (c) 2012 Business Wire. All of the news releases contained herein are protected by copyright and other applicable laws, treaties and conventions. Information contained in the releases is furnished by Business Wire's members, who warrant that they are solely responsible for the content, accuracy and originality of the information contained therein. All reproduction, other than for an individual user's personal reference, is prohibited without prior written permission.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com | BidVertiser